Skip to content

The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain

The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01954199
Enrollment
60
Registered
2013-10-01
Start date
2015-03-31
Completion date
2016-04-30
Last updated
2016-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Ache, Low Back Pain, Nerve Pain, Peripheral Nerve Injuries, Peripheral Nervous System Diseases, Sciatica, Signs and Symptoms

Keywords

Sciatica, Nerve pain, Low back pain

Brief summary

This study aims to verify if patients with nerve-related leg pain benefits from neurodynamic treatment over two weeks.

Detailed description

Nerve-related leg pain (NRLP) although less prevalent than low back pain itself, is associated with higher economic and social burden, and has been considered a predictor of chronicity and disability among subjects with low back pain. Numerous approaches are proposed for its management; however, evidence regarding the best therapeutic approach is lacking. Neurodynamic techniques are proposed to be effective to manage NRLP. Thus, this study aims to verify, through a randomized controlled trial, the effectiveness of a two-week program of neurodynamic techniques on pain and disability in individuals with NRLP.

Interventions

PROCEDURENeurodynamic Group

All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends. * In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen; * In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures; * In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner.

Sponsors

Federal University of Health Science of Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* unilateral leg pain (Intensity ≥ 3) * Pain distal to the buttocks * Reproduction of symptoms and change in symptoms with structural differentiation (cervical return to neutral position or ankle dorsiflexion) with slump test;

Exclusion criteria

* cauda equina syndrome; * bilateral leg pain; * crossed Lasègue sign; * previous surgery in the lumbar spine; * inflammatory arthropathies; * malignancy * being in litigation or in work-compensation due to back and/or leg pain * being receiving physiotherapy treatment at the time of baseline assessment

Design outcomes

Primary

MeasureTime frameDescription
Leg Pain IntensityTwo weeks after randomizationLeg Pain will be measured by a 0-10 Numeric Rating Scale (Pain NRS)
DisabilityTwo weeks after randomizationDisability will be measured by the Oswestry Disability Index (ODI)

Secondary

MeasureTime frameDescription
Leg pain IntensityFour weeks after randomizationLeg Pain will me measured by a 0-10 Pain NRS
DisabilityFour weeks after randomizationDisability will be measured by the Oswestry Disability Index (ODI)
Back pain intensityTwo weeks after randomizationBack Pain will me measured by an 0-10 Pain NRS
Distribution of SymptomsTwo weeks, Four weeks after randomizationDistribution of symptoms will me measured by a body diagram
FunctionTwo weeks, Four weeks after randomizationFunction will be measured by the Patient-Specific Functional Scale (PSFS)
Global Perceived EffectTwo weeks, Four weeks after randomizationGlobal Perceived Effect will be measured by an 11-point (-5 to +5) Global Perceived Effect Scale

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026